Experience

Davis Polk advised the joint book-running managers on an SEC-registered offering by Abbott Laboratories of $650 million aggregate principal amount of 1.150% notes due 2028 and $650…

Davis Polk advised the representative of the initial purchasers of a Rule 144A/Regulation S offering by Acadia Healthcare Company, Inc. of $450 million aggregate principal amount of its 5…

Davis Polk advised Amdocs Limited on its $650 million SEC-registered debt offering of 2.583% notes due 2030.   Amdocs Limited is a leading software and services provider to…

Davis Polk advised the dealer managers in connection with Danske Bank A/S’s offer to exchange any and all of its outstanding 5.000% non-preferred senior notes due 2022 for its newly issued…

Davis Polk advised the representatives of the underwriters, in connection with the offering of $4.5 billion aggregate principal amount of notes issued by Merck & Co., Inc. The…

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering by Viasat, Inc. of $400 million aggregate principal amount of its 6.500%…

We are advising Digicel in connection with the transactions

Davis Polk advised the sole book-running manager in an SEC-registered offering by Amerant Bancorp Inc. of $60 million aggregate principal amount of 5.750% notes due 2025. The notes are…

Davis Polk advised the initial purchaser in connection with a Rule 144A offering by CryoLife, Inc. of $100 million aggregate principal amount of its 4.250% convertible senior notes due 2025…

Davis Polk achieved a significant victory this week for its client, the New York Stock Exchange (“NYSE”), in a dispute between the three largest U.S. stock-exchange groups and the…